telisotuzumab
abbvie
['telisotuzumab vedotin', 'teliso', 'vedo', ' vedo']
dr. ross camidge stated that met amplification seemed to enrich response rate to telisotuzumab vedotin adc but responses also occurred in pts w/ cmet overexpression without amplification: #asco23 
A group of EGFR+ lung cancer patients who are resistant to targeted treatment. Sharing support & research news, accelerating research, improving outcomes. #lcsm